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Global research in the field of pharmacology has not yet found effective drugs to treat
Alzheimer’s disease (AD). Thus, alternative therapeutic strategies are under investigation,
such as neurostimulation by physical means. Radio electric asymmetric conveyer (REAC) is
one of these technologies and has, until now, been used in clinical studies on several psy-
chiatric and neurological disorders with encouraging results in the absence of side effects.
Moreover, studies at the cellular level have shown that REAC technology, with the appro-
priate protocols, is able to induce neuronal differentiation both in murine embryonic cells
and in human adult differentiated cells. Other studies have shown that REAC technology is
able to positively influence senescence processes. Studies conducted on AD patients and
in transgenic mouse models have shown promising results, suggesting REAC could be a
useful therapy for certain components of AD.
Keywords: Alzheimer’s disease, brain stimulation, brain modulation, neurodegenerative disease, senescence,
motor disorders, regenerative medicine, REAC technology
INTRODUCTION
Global research in the field of pharmacology has not yet found
effective drugs to treat Alzheimer’s disease (AD). As an alternative,
new therapeutic strategies are under investigation and clinical test-
ing. In particular, neurostimulation by physical means is regarded
as a promising strategy for symptomatic therapies for memory
and psychiatric symptoms (1), and also to counteract amyloid
accumulation (2) and modulate neuroplasticity (3).
Currently, the neurostimulation technologies most prevalent
in psychiatry are transcranial magnetic stimulation (TMS), deep
brain stimulation (DBS), vagus nerve stimulation (VNS), and
transcranial direct current stimulation (tDCS). A new technol-
ogy for bio and neuromodulation has been recently developed,
termed radio electric asymmetric conveyer (REAC) technol-
ogy (4, 5).
Until now, REAC technology has been used in clinical studies
on several psychiatric and neurological disorders with encourag-
ing results in the absence of side effects (6–15). Studies have also
been conducted in AD patients with promising results (16–18).
Moreover, studies at the cellular level have shown that REAC tech-
nology, with the appropriate protocols, is able to induce neuronal
differentiation both in murine embryonic cells and in human
adult differentiated cells (19–21). Other studies have shown
that REAC technology is able to positively influence senescence
processes (22, 23).
SIMILARITIES AND DIFFERENCES BETWEEN REAC
TECHNOLOGY AND OTHER
NEUROSTIMULATION–NEUROMODULATION TECHNIQUES
REAC technology is based on the use of radio fields concentrated
in an asymmetrical way. This innovative technology (1, 2) uses
very weak emissions in the radio frequency range, usually 2.4, 5.8,
or 10.5 GHz. The current models of REAC devices use only 2.4 or
5.8 GHz emissions, such as those issued by common Wi-Fi devices.
These particular characteristics of REAC technology make it com-
pletely distinct from all other neurostimulation–neuromodulation
technologies (24).
REAC TECHNOLOGY OPERATING CHARACTERISTICS
REAC technology is independent of the radio frequency emission
used. REAC devices use only frequencies of very weak intensity
(2.4 and 5.8 GHz) because these are the most widely used and
permitted at the international level (i.e., Wi-Fi). REAC technology
is effective at very low power levels – approximately 2 mW at the
emitter. Higher powers alter its mechanism of action. Emission
power is typically kept constant for all protocols, and instead, the
number of pulses and the duty cycle are varied.
The peculiarity of REAC technology is not the emission, but
the particular physical link between the device and the patient’s
body. This link is represented by the probe-asymmetric conveyer.
This is the ultimate innovation of REAC technology, covered by
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international patents (4, 5) and other patents in progress. Solely
thanks to the conveyer (asymmetric probe), the REAC emission
can interact with the biological tissues of the human body without
depth limits and in a very innovative way. This interaction gener-
ates induced radio frequency microcurrents in tissues that vary
according to their molecular characteristics. The sum of these
induced radio frequency microcurrents gives rise to a resulting
microcurrent generated by the tissue of the subject. This resulting
microcurrent, which we can term “autologous,” is concentrated by
the probe-asymmetric conveyer of the device and exerts a ther-
apeutic effect, which opens up new perspectives in the ambit of
treatments through physical devices.
Thanks to the peculiarities of its mechanism of action, REAC
technology has no limits of action related to the depth of the
tissue to be treated, and thus, organs deep within the body can
also be treated. Moreover, due to the nature of its mechanism of
action, REAC technology is safe, painless, and non-invasive. Its
application is rapid and has no contraindications or known side
effects.
Administration methods
REAC technology’s key feature is to concentrate the induced
microcurrents that are generated in the body. Therapeutic treat-
ments with REAC technology are administered by the application
of the cable probe of the REAC device on specific points of the
body. The duration of each treatment depends on the type of
protocol used and varies from the millisecond to hour timescale.
Until now, REAC therapies have utilized two neuromodula-
tion protocols, Neuro Postural Optimization (NPO) and Neuro
Psycho Physical Optimization (NPPO). The NPO protocol con-
sists of a single 250 ms REAC pulse and is designed to determine
initial efficacy of neuromodulation. This effect is particularly sta-
ble over time and capable of determining positive neuromotor
effects, subjective and objective, detectable with functional mag-
netic resonance imaging (fMRI) (25–27). The NPPO consists of
seven 500 ms REAC pulses, administered in a precise sequence.
Each NPPO treatment cycle consists of 18 sessions. This NPPO
protocol has been shown to result in the improvement of various
mental and psychiatric disorders (7–10, 12–15).
Currently, it is not possible to determine how many treatment
cycles are necessary to prevent or counteract the progression of
AD; however, we assume that the therapeutic approach should be
chronic, specifically three to four NPPO treatment cycles per year.
New therapeutic treatments for regenerative medicine are
currently being tested in animal models.
REAC TECHNOLOGY EFFICACY
LONG-LASTING CHANGES IN BRAIN ACTIVATION INDUCED BY REAC
TECHNOLOGY PULSES AND EFFICACY IN MOTOR CONTROL
In fMRI studies (25–27) on healthy subjects, brain activity has
been shown to be sensitive to REAC neuromodulation treatment
administered according to the NPO. REAC-NPO is thought to
modulate and optimize motor and postural strategies (28), thus
inducing neuromodulation. It is possible to highlight this neu-
romodulation though the fMRI BOLD signal via reductions in
signals from motor regions activated by simple motor tasks like
finger tapping (26) or leg flexion (25, 27). These BOLD signal
spatial reductions in REAC-NPO-treated groups are particularly
noticeable in cerebellar and ponto-mesencephalic areas, where the
signal completely disappears.
These findings, which can be interpreted as a functional opti-
mization of the brain structures that govern the coordination of
motor control and balance, led us to hypothesize that REAC-NPO
could be useful in the treatment of motor disorders. In AD patients,
motor disorders are more evident in the later stages of the disease,
when deficits in gait and balance, as well as other manifestations
of motor deterioration, emerge. This condition has direct con-
sequences on quality of life and patient and caregiver suffering.
On this basis of these observations, we, therefore, investigated
whether the positive results of REAC-NPO treatment could also
be obtained in patients with advanced AD (17).
We obtained confirmation of our hypothesis in randomized,
controlled trials where we also investigated the feasibility, safety,
and short-term motor effects of brain stimulation with REAC-
NPO in patients with advanced AD. The results showed that
REAC-NPO improved gait and number of steps per second. These
results hold some promise for a role of REAC in the treatment of
motor deterioration in AD. In fact, on the basis of its non-invasive,
painless, and safe nature, REAC seems particularly attractive for
treating patients with advanced AD who are often elderly and
frail.
REAC ELECTROPHYSIOLOGICAL EFFECTS ON NEURAL ACTIVITY IN THE
SOMATOSENSORY THALAMOCORTICAL LOOP
The effects of REAC neuromodulatory protocols on neuronal
spiking and synaptic (local field potential) activity have been
recorded simultaneously from two brain regions – the somatosen-
sory thalamus and cortex. The application of REAC in rats during
electrophysiological recordings showed significant effects both
on normal animals and an experimental model of chronic pain
(the chronic constriction injury, or CCI, model) with anom-
alous neuronal discharge patterns – namely increases in discharge
rate, hyper-responsiveness to light and noxious stimuli, and long
after-discharges after stimulus withdrawal, all complements to the
semeiotic clinical signs of allodynia, hyperalgesia, and persistent
pain after stimulus discontinuation.
The effects of REAC, evident both in spontaneous and
stimulus-evoked activity, were characterized by significant
increases in spiking frequency (>25–30% of the overall mean fir-
ing rate) and local field potential synchrony in both control and
CCI animals. Overall, these results suggest profound influences
of REAC on brain functional network architecture at the cellu-
lar level, even in strongly perturbed networks such as the CCI
chronic pain model. These findings at the neuronal scale supple-
ment the previous fMRI data that reported REAC-induced BOLD
signal reductions in motor regions activated by simple motor tasks
involving finger tapping (26), leg flexion (27), and postural balance
control (28).
REAC COGNITIVE EFFECTS ON AD
The NPPO protocol has demonstrated significant efficacy in
improving psychiatric disorders such as anxiety, depression, and
bipolar disorder. Based on these results, we hypothesized that
NPPO could be helpful in the treatment of behavioral symptoms
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and cognitive functioning in AD patients and in several forms of
behavioral and cognitive-impairment disorders.
In a study conducted on eight patients diagnosed with AD
according to the DSM-IV-TR criteria, and presenting with behav-
ioral and/or psychiatric disturbances, we observed that the
REAC-NPPO protocol is able to enhance cognitive and behavioral
functioning. All measures of cognitive functioning were signif-
icantly improved after the initial REAC-NPPO treatment and
continued to improve after the subsequent REAC-NPPO treat-
ment cycle. Similarly, all behavioral measurements were positively
affected after the first REAC-NPPO treatment, and most contin-
ued to improve after the subsequent REAC-NPPO treatment cycle.
We also confirmed that REAC-NPPO treatment has a high safety
and tolerability profile. Based on these observations, we hypoth-
esize that REAC-NPPO treatment may be useful not only for AD
patients but also for other forms of dementia (i.e., vascular demen-
tia or mixed conditions). Further studies are needed to confirm this
hypothesis.
STUDIES IN ANIMAL MODELS OF AD
REAC technology is also under study in animal models of
Alzheimer disease. In particular, the effects of REAC exposure
on the main landmark symptoms of AD (i.e., learning and
memory impairment, as well as amyloid deposition and neu-
roinflammation) are being investigated in Tg2576 mice. Tg2576
mice overexpress the Swedish double mutant form of APP-
swe695 (K670N-M671L) under the hamster PrP promoter, on
a background of C57BL/6 and SJL mouse strains (29) and is a
widely used model to test novel AD treatments in a translational
approach (30, 31). Learning and memory deficits appear quite
early in this mouse model, well before plaque deposition (32),
and are associated with synaptic and neurotransmitter dysfunc-
tions involving acetylcholine, GABA, and glutamate (33, 34). In
old and very old animals, classical amyloid plaque deposition,
tau hyper-phosphorylation, and neuroinflammation (34) are evi-
dent. In these very old animals, we have tested the effects of
2-week exposures to REAC (6 h per day) on learning and memory,
locomotion, amyloid deposition, and neuroinflammation. Prelim-
inary results indicate that REAC exposure increases spontaneous
locomotion and dramatically decreases neuroinflammation, as
detected by decreased expression of the microglia marker Iba1 and
the astroglial marker GFAP. These preliminary results suggest that
REAC is an effective technology for decreasing neuroinflammation
associated with amyloid plaque deposition.
REAC INDUCES DIRECT NEURONAL DIFFERENTIATION IN MURINE
EMBRYONIC AND HUMAN DIFFERENTIATED CELLS
The clinical results obtained with REAC technology led us to
investigate the biological and molecular mechanisms that would
allow us to understand the clinical outcomes of its use. Studies
were conducted with specific protocols for cell culture in order
to investigate REAC efficacy at the cellular level. In particular,
we investigated the effects of REAC stimulation on the transcrip-
tion of neurogenin1 during neurogenesis in murine embryonic
(ES) (21) and human differentiated cells (19, 20). We provided
evidence that REAC exposure resulted in the induction of tar-
geted genes controlling neurogenic and myogenic commitment,
followed by the appearance of the corresponding phenotypes,
in mouse ES cells. Moreover, we demonstrated the effectiveness
of REAC treatment in downregulating expression of the genes
controlling pluripotency in mouse ES cells after 24 h of exposure.
We exposed cells to REAC by immersing the conveyer elec-
trodes in the culture medium. Cell responses were investigated by
real-time PCR, Western blot, and confocal microscopy. RF burst
duration, radiated power, electric and magnetic fields, specific
absorption rate, and current density in culture medium were mon-
itored. REAC stimulation primed transcription of genes involved
in cardiac (GATA4, Nkx-2.5, and prodynorphin), skeletal muscle
(myoD), and neuronal (neurogenin1) commitment, while down-
regulating the self-renewal/pluripotency-associated genes Sox2,
Oct4, and Nanog. REAC exposure enhanced the expression of car-
diac, skeletal, and neuronal lineage-restricted marker proteins. The
results obtained with murine embryonic stem cells were replicated
in human adipose-derived stem cells (hADSCs) and fibroblasts.
These studies revealed the feasibility of enforcing a long-lived and
inexpensive commitment of hADSCs and fibroblasts to multiple
complex lineages without the use of intricate chemistry or viral
transduction. This opens a real perspective for the immediate and
safe use of REAC in human beings. On this basis, REAC technology
promises to become a new therapeutic opportunity in the field of
neurodegenerative diseases that can induce both neuromodulation
and regenerative processes.
REAC EFFICACY IN ANTI-SENESCENCE
Since AD is related to aging, we investigated whether REAC
technology could counteract the aging process itself. Beta-
galactosidase is a marker of senescence and is also related to AD.
We, therefore, investigated whether REAC stimulation is effec-
tive in counteracting the expression of beta-galactosidase and of
senescence-associated gene expression patterning engaged during
prolonged culture of hADSCs. We demonstrated that REAC treat-
ment remarkably influences cell viability and induces a significant
downregulation of beta-galactosidase staining and the expres-
sion of senescence mediator genes. Moreover, REAC-exposed
hADSCs maintained their typical fibroblast-like morphology
and exhibited a multilineage potential even at late passages,
as shown by the remarkable preservation of commitment to
osteogenic, adipogenic, chondrogenic, and vasculogenic fates,
both at the morphological and gene expression levels. We demon-
strated that REAC is able to counteract degenerative senes-
cence processes in vitro, as well as the biochemical and mor-
phological changes occurring in stem cells during aging. These
results support the future clinical application of REAC tech-
nology as a potential tool for blunting age-related degenerative
diseases.
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